The immunopeptidomics and proteomics datasets from the breast cancer cell line MDA-MB-231 (28) were appropriate for comparison as these are cancer cells that had also been treated with IFNγ for 48 hours (Fig. 4A). This evidence concerns the gene IFNG and breast carcinoma.